Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax (Nasdaq: NVAX) will participate in the Jefferies London Healthcare Conference with a fireside chat on November 17, 2026.
The chat in London, United Kingdom, starts at 5:00 p.m. GMT. A live webcast will be available on the Events & Presentations page at ir.novavax.com, with a replay available for 30 days following the presentation.
Novavax (NVAX) reported third-quarter 2026 revenue of $68 million, down year over year, while narrowing its net loss. Revenue declined 3% from $70 million; net loss narrowed to $31 million from $202 million. Product sales rose 91% to $26 million, while licensing, royalties and other revenue fell 25% to $43 million.
Novavax raised its full-year non-GAAP adjusted revenue outlook to $385–$415 million from $235–$275 million, including a $125 million milestone earned in October when Sanofi began a European Phase 3 influenza-COVID-19 combination vaccine trial. Expected combined research and development and administrative expenses narrowed to $375–$395 million. Cash, cash equivalents, marketable securities and restricted cash totaled $627 million at September 30, versus $751 million at year-end 2025. Novavax anticipates its C. difficile vaccine could enter clinical testing as early as 2027.
Novavax (Nasdaq: NVAX) earned a $125 million milestone payment as Sanofi initiated a Phase 3 influenza-COVID-19 combination vaccine trial in Europe. The milestone was triggered by dosing the fifth patient. The trial assesses safety and immune responses in adults aged 60 and older, combining Novavax's Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose flu vaccine.
The partnership has generated over $1 billion in revenue for Novavax. Novavax is eligible for a $75 million milestone upon successful manufacturing technology transfer, anticipated in mid-2027, and $225 million upon a U.S. combination-vaccine launch after Sanofi completes U.S. clinical and regulatory requirements. The agreement also provides royalties on Sanofi's Nuvaxovid sales and combination products using Nuvaxovid, plus milestones and royalties for new Sanofi vaccines using Novavax's Matrix-M adjuvant.
Novavax (NVAX) plans to release its third quarter 2026 financial results before U.S. financial markets open on November 5, 2026. Management will then host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights. A webcast replay will be available approximately two hours after the event.
Novavax (NVAX) will participate in two investor conferences in New York in September 2026, featuring live fireside chat webcasts.
Management will join the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 9:45 a.m. EDT and Citi's 2026 BioPharma Back to School Conference on Thursday, September 10, 2026, at 10:00 a.m. EDT. Webcasts and 30‑day replays will be available on the company’s investor relations website.
Novavax (Nasdaq: NVAX) announced that its partners have received approvals for an XFG-variant–adapted Nuvaxovid™ COVID-19 vaccine for the 2026-2027 vaccination season in major markets including the U.S., European Union and Japan, positioning the company to continue earning royalties on net sales.
According to Novavax, Sanofi leads commercialization in most major markets, is expanding U.S. marketing and is launching in Germany, Canada and other markets from 2026 onward under a 2024 collaboration and license agreement that provides ongoing royalties. In Japan, Takeda commercializes Nuvaxovid, which was the second-most used COVID-19 vaccine in the 2025-2026 season, with significantly higher delivery volumes and site numbers year over year, triggering annual milestones and seasonal royalties for Novavax.
The company highlighted Phase 4 COMPARE study results from Sanofi showing Nuvaxovid’s favorable tolerability profile versus a next-generation mRNA vaccine, and described the protein-based, non-mRNA formulation, Matrix-M® adjuvant technology and standard 2°–8°C storage as key product attributes.
Novavax (Nasdaq: NVAX) reported second quarter 2026 total revenue of $57 million, down 76% from $239 million a year earlier, mainly due to prior-year milestone and amendment revenue. Product sales were $19 million, up 76% on higher Matrix-M adjuvant demand and partner sales.
GAAP R&D expense was $71 million and SG&A $27 million; Non-GAAP combined R&D and SG&A fell to $74.8 million from $116.4 million. Net loss was $53 million versus net income of $107 million in Q2 2025. Cash, cash equivalents, marketable securities and restricted cash totaled $724 million at June 30, 2026.
Novavax lowered 2026 combined R&D and SG&A guidance by $10 million at the midpoint, maintained Non-GAAP combined expense guidance, and raised its 2026 Adjusted Total Revenue framework to $235–$275 million. The Sanofi partnership continues, with eligibility for up to $125 million in Phase 3 CIC trial initiation milestones, a $75 million manufacturing tech transfer milestone expected upon completion around mid-2027, high-teens to low-twenties royalties on Sanofi global Nuvaxovid sales, and additional Matrix-M–related milestones.
Novavax (Nasdaq: NVAX) will release its second quarter 2026 financial results before U.S. market open on Thursday, August 6, 2026, and will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and operational highlights.
Investors can join via live webcast at ir.novavax.com/events or by phone using U.S. dial-in (+1) 888-880-3330 or international dial-in (+1) 646-357-8766. A replay will be available online and by phone at (+1) 800-770-2030 (U.S.) or (+1) 609-800-9909 (international) with passcode 9097916# starting about two hours after the event.
Novavax (Nasdaq: NVAX) will participate in the 2026 Jefferies Global Healthcare Conference in New York, NY.
The company is scheduled for a fireside chat on Thursday, June 4, 2026, from 10:30–11:00 a.m. Eastern Time. A live webcast and 30-day replay will be available on its investor website.
Novavax (Nasdaq: NVAX) will participate in the BofA Securities 2026 Health Care Conference with a fireside chat on Wednesday, May 13, 2026 at 3:00–3:30 p.m. PT in Las Vegas. A webcast will be available on the company website and a replay will be accessible for 30 days.